EcoDrugPlus

Epidermal Growth Factor Receptor-Like

Ensembl ID : ENSAMXG00000012474
Gene Symbol: LOC103031629
3 Cross references
212 Possible Orthologues:

Epidermal Growth Factor Receptor-Like

Ensembl ID : ENSAMXG00000015959
Gene Symbol: LOC103032492
2 Cross references
213 Possible Orthologues:

Epoxide Hydrolase 2

Ensembl ID : ENSAMXG00000000817
Gene Symbol: EPHX2
3 Cross references
204 Possible Orthologues:

Equilibrative Nucleoside Transporter 1

Ensembl ID : ENSAMXG00000003715
Gene Symbol: LOC103023173
3 Cross references
204 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSAMXG00000000253
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSAMXG00000016428
Gene Symbol: ERBB3
1 Cross references
211 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3b

Ensembl ID : ENSAMXG00000018110
Gene Symbol: ERBB3B
1 Cross references
210 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSAMXG00000013230
Gene Symbol: ERBB4
3 Cross references
227 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSAMXG00000002862
Gene Symbol: ERBB4
1 Cross references
227 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSAMXG00000018917
Gene Symbol: ERBB4
1 Cross references
225 Possible Orthologues:

Estrogen Receptor

Ensembl ID : ENSAMXG00000006267
Gene Symbol: LOC103043741
3 Cross references
215 Possible Orthologues:

Estrogen Receptor 2b

Ensembl ID : ENSAMXG00000008365
Gene Symbol: ESR2B
1 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).